Johnston A, Warrington S, Turner P
Br J Clin Pharmacol. 1985 Oct;20(4):333-8. doi: 10.1111/j.1365-2125.1985.tb05073.x.
The pharmacokinetics of a single 300 mg oral dose of flecainide were studied in eight healthy volunteers on four separate occasions under different conditions of urinary pH. The urinary pH of the volunteers was manipulated chemically to produce four distinct groups spanning the range of urinary pH (pH 5-8). Neither the rate nor extent of flecainide absorption was significantly affected by changes in urinary pH. However the plasma elimination of flecainide was found to be inversely proportional to urinary pH and the volunteers' mean elimination half-life ranged between 10.7 +/- 3.2 h (s.d.) at the extreme acid pH and 17.6 +/- 6.3 h at the extreme alkali pH. The urinary elimination and renal clearance of flecainide decreased with increasing urinary pH. The influence of changes in urinary pH on the pharmacokinetics of flecainide will contribute to the normal variability in flecainide serum concentrations seen in patients and should be considered in patients who have adverse reactions to the drug at low dosage or who fail to respond at high doses.
在八个健康志愿者身上,于四种不同尿pH条件下,分四次研究了单次口服300毫克氟卡尼的药代动力学。通过化学方法调节志愿者的尿pH,以产生涵盖尿pH范围(pH 5 - 8)的四个不同组。氟卡尼的吸收速率和程度均未因尿pH的变化而受到显著影响。然而,发现氟卡尼的血浆消除与尿pH成反比,志愿者的平均消除半衰期在极端酸性pH时为10.7 +/- 3.2小时(标准差),在极端碱性pH时为17.6 +/- 6.3小时。氟卡尼的尿排泄和肾清除率随尿pH升高而降低。尿pH变化对氟卡尼药代动力学的影响将导致患者中观察到的氟卡尼血清浓度的正常变异性,对于低剂量时对该药物有不良反应或高剂量时无反应的患者应予以考虑。